Nerve-sparing Robot-assisted Retroperitoneal Lymph Node Dissection: The Monoblock Technique.

Lymph node dissection Minimally invasive surgical procedure Nonseminomatous germ cell tumor Retroperitoneal neoplasm Seminoma Testis cancer

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Oct 2021
Historique:
accepted: 21 07 2021
entrez: 20 10 2021
pubmed: 21 10 2021
medline: 21 10 2021
Statut: epublish

Résumé

Retroperitoneal lymph node dissection (RPLND) is a treatment option for men with stage 1 or 2 testis cancer and the standard of care for men with postchemotherapy retroperitoneal residual disease. Given the morbidity of RPLND, four important surgical modifications have been proposed: minimally invasive access, nerve-sparing resection, template resection, and en-bloc resection. To describe the surgical steps and perioperative outcomes of robotic nerve-sparing unilateral template RPLND with en-bloc resection (roboRPLND-NS+). From 2017 to 2019, five patients with suspicion of retroperitoneal metastatic testicular cancer on abdominopelvic computed tomography underwent roboRPLND-NS+ at a single referral center. All surgeries were carried out by a single surgeon who has performed more than 500 extended and more than 50 super-extended robot-assisted lymph node dissections. A lateral transperitoneal robotic approach with a da Vinci Xi Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) in six-arm configuration was used. The sympathetic chains, postganglionic sympathetic fibers, and hypogastric plexus were preserved as much as possible to ensure a nerve-sparing procedure. The template borders consisted of the renal vein cranially, the ureter laterally, the interaortocaval space medially, the common iliac artery caudally, and the psoas muscle dorsally for the right and left modified RPLND templates. Lymph nodes and the surrounding fatty tissue were progressively resected from the common iliac vessels and the abdominal aorta using the split-and-roll technique, and all of the template tissue was resected as a single specimen. Intraoperative and postoperative complications were recorded. Lymph node yield and perioperative and postoperative oncological and functional outcomes were measured. The median patient age was 38 yr (interquartile range [IQR] 32-41) and the median operative time was 274 min (IQR 238-280). Node metastases were pathologically confirmed in three patients. The median number of lymph nodes removed was 19 (IQR 18-21), and the median number of positive lymph nodes was 2 (IQR 1-3). No patient experienced intraoperative or postoperative complications. The postoperative hospital stay was either 3 or 4 d. Maintenance of antegrade ejaculation was achieved in all patients. After median follow-up of 15 mo (IQR 14-30), all patients were alive and no recurrence was observed. Limitations include the low number of patients and the single surgeon experience. RoboRPLND-NS+ is a safe and feasible technique that allows removal of a high number of lymph nodes with good functional outcomes. Short-term survival outcomes were excellent, with no recurrences or deaths recorded. We describe a feasible and safe robot-assisted surgical procedure for removal of lymph nodes in patients with testicular cancer. Our technique has potential to decrease the medical problems arising as side effects of the surgery while achieving good cancer control.

Sections du résumé

BACKGROUND BACKGROUND
Retroperitoneal lymph node dissection (RPLND) is a treatment option for men with stage 1 or 2 testis cancer and the standard of care for men with postchemotherapy retroperitoneal residual disease. Given the morbidity of RPLND, four important surgical modifications have been proposed: minimally invasive access, nerve-sparing resection, template resection, and en-bloc resection.
OBJECTIVE OBJECTIVE
To describe the surgical steps and perioperative outcomes of robotic nerve-sparing unilateral template RPLND with en-bloc resection (roboRPLND-NS+).
DESIGN SETTING AND PARTICIPANTS METHODS
From 2017 to 2019, five patients with suspicion of retroperitoneal metastatic testicular cancer on abdominopelvic computed tomography underwent roboRPLND-NS+ at a single referral center. All surgeries were carried out by a single surgeon who has performed more than 500 extended and more than 50 super-extended robot-assisted lymph node dissections.
SURGICAL PROCEDURE METHODS
A lateral transperitoneal robotic approach with a da Vinci Xi Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) in six-arm configuration was used. The sympathetic chains, postganglionic sympathetic fibers, and hypogastric plexus were preserved as much as possible to ensure a nerve-sparing procedure. The template borders consisted of the renal vein cranially, the ureter laterally, the interaortocaval space medially, the common iliac artery caudally, and the psoas muscle dorsally for the right and left modified RPLND templates. Lymph nodes and the surrounding fatty tissue were progressively resected from the common iliac vessels and the abdominal aorta using the split-and-roll technique, and all of the template tissue was resected as a single specimen. Intraoperative and postoperative complications were recorded.
MEASUREMENTS METHODS
Lymph node yield and perioperative and postoperative oncological and functional outcomes were measured.
RESULTS AND LIMITATIONS CONCLUSIONS
The median patient age was 38 yr (interquartile range [IQR] 32-41) and the median operative time was 274 min (IQR 238-280). Node metastases were pathologically confirmed in three patients. The median number of lymph nodes removed was 19 (IQR 18-21), and the median number of positive lymph nodes was 2 (IQR 1-3). No patient experienced intraoperative or postoperative complications. The postoperative hospital stay was either 3 or 4 d. Maintenance of antegrade ejaculation was achieved in all patients. After median follow-up of 15 mo (IQR 14-30), all patients were alive and no recurrence was observed. Limitations include the low number of patients and the single surgeon experience.
CONCLUSIONS CONCLUSIONS
RoboRPLND-NS+ is a safe and feasible technique that allows removal of a high number of lymph nodes with good functional outcomes. Short-term survival outcomes were excellent, with no recurrences or deaths recorded.
PATIENT SUMMARY RESULTS
We describe a feasible and safe robot-assisted surgical procedure for removal of lymph nodes in patients with testicular cancer. Our technique has potential to decrease the medical problems arising as side effects of the surgery while achieving good cancer control.

Identifiants

pubmed: 34667953
doi: 10.1016/j.euros.2021.07.004
pii: S2666-1683(21)00135-X
pmc: PMC8505201
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1-7

Informations de copyright

© 2021 The Author(s).

Références

J Clin Oncol. 2008 Jun 20;26(18):2966-72
pubmed: 18458040
J Clin Oncol. 2020 Feb 20;38(6):584-592
pubmed: 31821065
J Clin Oncol. 2005 Oct 1;23(28):6999-7004
pubmed: 16192587
Eur Urol. 2017 Nov;72(5):814-820
pubmed: 28325537
Eur Urol. 2020 Sep;78(3):424-431
pubmed: 32327264
Urology. 2009 Feb;73(2):328-31; discussion 331-2
pubmed: 19022490
J Urol. 1990 Aug;144(2 Pt 1):287-91; discussion 291-2
pubmed: 2165181
World J Urol. 2021 Feb;39(2):389-397
pubmed: 32328779
J Urol. 2020 Dec;204(6):1242-1248
pubmed: 32717162
J Urol. 2008 Oct;180(4):1348-52; discussion 1352-3
pubmed: 18707723
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Urology. 2017 Nov;109:38-43
pubmed: 28827196
Eur Urol. 2010 Dec;58(6):912-8
pubmed: 20817343
J Clin Oncol. 2005 Sep 1;23(25):6149-56
pubmed: 16135481
J Urol. 1988 Jun;139(6):1220-4
pubmed: 2836633
J Clin Oncol. 2007 Dec 10;25(35):5597-602
pubmed: 18065732
J Urol. 2020 Jul;204(1):96-103
pubmed: 32003612
J Clin Oncol. 2019 Aug 1;37(22):1919-1926
pubmed: 30802156
Medicine (Baltimore). 2017 Dec;96(49):e8938
pubmed: 29245261
Eur Urol. 2015 Dec;68(6):1054-68
pubmed: 26297604

Auteurs

Luca Afferi (L)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Philipp Baumeister (P)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Christian Fankhauser (C)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Livio Mordasini (L)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Marco Moschini (M)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Fabian Aschwanden (F)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Agostino Mattei (A)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Classifications MeSH